Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Expert Opinion on Drug Safety

Volumn 14, Issue 6, 2015, Pages 935-955

  Banach, Maciej ^a   Rizzo, Manfredi ^b   Toth, Peter P ^c   Farnier, Michel ^d   Davidson, Michael H ^e   Al Rasadi, Khalid ^f   Aronow, Wilbert S ^g   Athyros, Vasilis ^h   Djuric, Dragan M ⁱ   Ezhov, Marat V ^j   Greenfield, Robert S ^k   Hovingh, G Kees ^l   Kostner, Karam ^m   Serban, Corina ⁿ   Lighezan, Daniel ⁿ   Fras, Zlatko ^o   Moriarty, Patrick M ^p   Muntner, Paul ^q   Goudev, Assen ^r   Ceska, Richard ^s   Nicholls, Stephen J ^t   Broncel, Marlena ^a   Nikolic, Dragana ^b   Pella, Daniel ^u   Puri, Raman ^v   Rysz, Jacek ^a   Wong, Nathan D ^w   Bajnok, Laszlo ^x   Jones, Steven R ^y   Ray, Kausik K ^z   Mikhailidis, Dimitri P ^aa   more..

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF ILLINOIS   (United States)

^d Point Medical   (France)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^k California Heart Assoc   (United States)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

^m UNIVERSITY OF QUEENSLAND   (Australia)

ⁿ VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^o UNIVERSITY OF LJUBLJANA   (Slovenia)

^p UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^r UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^s CHARLES UNIVERSITY   (Czech Republic)

^t UNIVERSITY OF ADELAIDE   (Australia)

^u L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^v INDRAPRASTHA APOLLO HOSPITAL   (India)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x UNIVERSITY OF PÉCS   (Hungary)

^y JOHNS HOPKINS UNIVERSITY   (United States)

^z IMPERIAL COLLEGE LONDON   (United Kingdom)

^aa UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Definition; Muscle symptoms; Risk factors; Statin intolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; THYROXINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC ERROR; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; ENZYME ACTIVITY; GERIATRIC PATIENT; HEALTH CARE; HEART MUSCLE ISCHEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; LIVER DISEASE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MAJOR SURGERY; META ANALYSIS (TOPIC); MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; RHABDOMYOLYSIS; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RISK BENEFIT ANALYSIS; RISK FACTOR; STATIN INTOLERANCE; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DYSLIPIDEMIAS; MUSCULAR DISEASES;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES;

EID: 84929578095     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1039980     Document Type: Article

References (201)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
2. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15(12):MS1-5
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
4. Banach M, Mikhailidis DP. Statin therapy and new-onset diabetes: An attempt at recommendations. Exp Rev Endocrinol Metabol 2013;8(3):213-16
5. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311(14):1416-23
6. Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 2014. [Epub ahead of print]
7. Thompson PD, Clarkson P, Karas RH. Statin-Associated myopathy. JAMA 2003;289:1681-90
8. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statinassociated myalgia-A systematic review and meta-Analysis of 7 studies with 2420 patients. Int J Cardiol 2015;178:111-16
9. Banach M, Serban C, Sahebkar A, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of Coenzyme Q10 on Statin-Induced Myopathy: A Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc 2015;90(1):24-34
10. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-Associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015. [Epub ahead of print]
11. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150(12):858-68
12. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002;137(7):617-18
13. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97:6C-26C
14. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to Statins: Mechanisms and Management. Diabetes Care 2013;36:S325-30
15. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21(5):280-8
16. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-Analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16(2):132-43
17. Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014;46(5):947-61
18. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68
19. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83(6):687-700
20. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014. J Clin Lipidol 2014;8:S58-71
21. Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014;24(10):1057-66
22. Stephen K. Galson Acting Director U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA Rejection of Citizen Petition. Letter dated 11 March 2005, Food and Drug Administration Docket No. 2004P-0113/CP1
23. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
24. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96-103
25. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group1. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69
26. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91
27. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
28. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80
29. Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 2012;57:1959-64
30. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012;10:264-71
31. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs (2-28-2012). Available from: http://www.fda. gov/Drugs/DrugSafety/ucm293101.htm
32. Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women. Clin Lipidol 2012;7:267-70
33. Barylski M, Mayszko J, Rysz J, et al. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 2011;7(6):1055-66
34. Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and newonset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013;19(27):4904-12
35. Barylski M, Nikolic D, Banach M, et al. Statins and new-onset diabetes. Curr Pharm Des 2014;20(22):3657-64
36. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-Analysis of randomized statin trials. Lancet 2010;375:735-42
37. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-Analysis. Diabetes Care 2009;32:1924-9
38. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-Analysis. JAMA 2011;305:2556-64
39. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71
40. Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med 2014;174(7):1038-45
41. Golomb BA, Evans MA. Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism. Am J Cardiovasc Drugs 2008;8:373-418
42. Lim S, Despres J-P, Koh KK. Prevention of Atherosclerosis in Overweight/Obese Patients-In need of novel multi-targeted approaches. Circ J 2011;75(5):1019-27
43. Monda KL, Ballantyne CM, North KE. Longitudinal impact of physical activity on lipid profiles in middle-Aged adults: the Atherosclerosis Risk in Communities Study. J Lipid Res 2009;50(8):1685-91
44. Kearns AK, Bilbie CL, Clarkson PM, et al. The creatine kinase response to eccentric exercise with atorvastatin 10mg or 80mg. Atherosclerosis 2008;200(1):121-5
45. Meador BM, Huey KA. Statin-Associated myopathy and its exacerbation with exercise. Muscle Nerve 2010;42(4):469-79
46. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57(4):525-8
47. Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012;109(2):282-7
48. Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exerciseinduced skeletal muscle injury. Metabolism 1997;46(10):1206-10
49. Kokkinos PF, Faselis C, Myers J, et al. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013;381(9864):394-9
50. Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33(2):246-57
51. Kwak H-B, Thalacker-Mercer A, Anderson EJ, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52(1):198-207
52. Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259(2):263-8
53. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005;25(12):2560-6
54. Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metabol 2014;99(11):E2154-E61
55. Thompson PD, Parker B. Statins, Exercise, and Exercise Training. J Am Coll Cardiol 2013;62(8):715-16
56. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008;24(11):3059-62
57. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statinassociated myotoxicity. Curr Opin Pharmacol 2008;8:333-8
58. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
59. Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259:263-8
60. Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. Am Fam Physician 2012;86:244-51
61. Arruda AP, Ketzer LA, Nigro M, et al. Cold tolerance in hypothyroid rabbits: role of skeletal muscle mitochondria and sarcoplasmic reticulum Ca2+ ATPase isoform 1 heat production. Endocrinology 2008;149:6262-71
62. Farias Moeller R, Zecavati N, Sherafat-Kazemzadeh R, et al. Adolescent with rhabdomyolysis due to undiagnosed hypothyroidism. Case Rep Pediatr 2011;2011:670673
63. Lando HM, Burman KD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract 2008;14:726-31
64. Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007;119:374-6
65. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-9
66. Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007;53:428-31
67. Al-Salameh A, Bihan H, Keller-Petrot I, et al. Statins should be used with greater caution in patients undergoing thyroid hormone withdrawal for radioactive iodine treatment. Thyroid 2011;21:457-8
68. Garber JR, Cobin RH, Gharib H, et al. for the American Association of Clinical Endocrinologists and the American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical Practice Guidelines for Hypothyroidism in Adults. Thyroid 2012;22:1200-35
69. Rando LP, Cording SA, Newnham HH. Successful reintroduction of statin therapy after myositis: was there another cause? Med J Aust 2004;180:472-3
70. Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: an update. Hormones (Athens) 2013;12:495-506
71. Duman D, Sahin S, Esertas K, Demirtunc R. Simvastatin improves endothelial function in patents with subclinical hypothyroidism. Heart Vessels 2007;22:88-93
72. Requena Carrión E, Ayala Jimenez L, Sierra Garcá F. Renal failure due to simvastatin-induced rhabdomyolysis in a patient with subclinical hypothyroidism. Farm Hosp 2010;34(1):45-6
73. Bryson CL, Au DH, Sun H, et al. Alcohol screening scores and medication nonadherence. Ann Intern Med 2008;149(11):795-804
74. Smit JW, Wijnne HJ, Schobben F, et al. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function. Ann Int Med 1995;122:678-80
75. Mukamal KJ, Smith CC, Karlamangla AS, Moore AA. Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. Am J Med 2006;119(5):434-40
76. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65
77. Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medicine; International Diabetes Federation Europe; European Heart Network. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012;19(4):585-667
78. Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
79. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:S69-76
80. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92
81. Athyros VG, Katsiki N, Tziomalos K, GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013;9(3):418-26
82. Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010;376:1882-3
83. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004;71:58-62
84. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80
85. Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-92
86. Hepatitis C. WHO Fact sheet N164. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
87. Wang C, Gale M Jr., Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18:425-34
88. Ali N, Allam H, Bader T, et al. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One 2013;8:e80304
89. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of antihepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007;105:145-50
90. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro antihepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009;50:6-16
91. Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-Analysis. Gastroenterology 2013;144:323-32
92. Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a metaanalysis of observational studies. Eur J Cancer Prev 2013;22:229-34
93. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81
94. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25(8):1995-2005
95. Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012;56:305-7
96. Bradley SM, Soine LA, Caldwell JH, Goldberg SL. Screening stress myocardial perfusion imaging and eligibility for liver transplantation. Am J Cardiol 2010;105:1010-13
97. Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly 2008;138:415-19
98. Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010;209:178-83
99. Cash WJ, O'Neill S, O'Donnell ME, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013;33:1166-74
100. Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010;55:2086-8
101. Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008;8:60-4
102. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins 'IDEAL' for non-Alcoholic fatty liver disease? Curr Med Res Opin 2014;30(2):229-31
103. Musso G, Gambino R, Cassader M, Pagano G. A meta-Analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104
104. Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
105. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805
106. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Smoking and nonalcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. J Hepatol 2012;57:476
107. Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-Alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71
108. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7
109. Tikkanen MJ, Fayyad R, Faergeman O, et al. On behalf of the IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-52
110. Nikolic D, Banach M, Nikfar S, Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-Analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important Int J Cardiol 2013;168(6):5437-47
111. Lonardo A, Sookoian S, Chonchol M, et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease-Atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013;19:5177-92
112. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2003;24(1):46-53
113. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when Expert Opin Pharmacother 2010;11(16):2665-74
114. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13(5):541-50
115. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51(15):1448-54
116. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and allcause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15(5):1307-15
117. Barylski M, Nikfar S, Mikhailidis DP, Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A metaanalysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:35-44
118. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. Bmj 2013;346:f880
119. Marenzi G, Cosentino N, Werba JP, et al. A meta-Analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 2015;183:47-53
120. Gluba A, Banach M, Hannam S, et al. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010;6(4):224-35
121. Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-Alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 2006;3(2):151-4
122. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Int Med 2014;160(3):182-9
123. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg J, Rich MW, editors. Tresch and Aronow's cardiovascular disease in the elderly. 5th edition. CRC Press; Boca Raton, London, New York: 2013. p. 67-103
124. Szadkowska I, Stanczyk A, Aronow WS, et al. Arch Gerontol Geriatr 2010;50:114-18
125. Novak LP. Aging, total body potassium, fat-free mass and cell mass in males and females between the ages of 18 and 85 years. J Gerontol 1972;27:438-43
126. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985;37:133-48
127. Cheng JWM, Frishman WH, Aronow WS. Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 2009;16:155-63
128. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
129. Thomas JE, Foody JM. Disorders of lipid metabolism. In: Aronow WS, Fleg JL, Rich MW, editors. Cardiovascular disease in the elderly. 4th edition. Informa Healthcare; New York, London: 2008. p. 159-78
130. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22
131. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
132. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005;352:1425-35
133. Roberts CGP, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-Analysis. J Gerontol Med Sci 2007;62A:879-87
134. Martin SS, Blumenthal RS. Disorders of lipid metabolism. In: Aronow WS, Fleg J, Rich MW, editors. Tresch and Aronow's cardiovascular disease in the elderly. 5th edition. CRC press; Boca Raton, London, New York: 2013. p. 121-42
135. Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002;11:48-55
136. Rizzo M, Nikolic D, Banach M, Montalto G. Statin treatment in the elderly: how much do we know? Arch Med Sci 2013;9(4):585-8
137. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): doubleblind, randomised placebo-controlled trial. Lancet 2004;363(9426):2015-21
138. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methylglutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012;32(2):287-94
139. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-82
140. de Jong HJ, Saldi SR, Klungel OH, et al. Statin-Associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One 2012;7:e41289
141. de Jong HJ, Klungel OH, van Dijk L, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012;71(5):648-54
142. Moulis G, Bene J, Sommet A, et al. French Association of PharmacoVigilance Centres. Statin-induced lupus: a case/noncase study in a nationwide pharmacovigilance database. Lupus 2012;21:885-9
143. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: A systematic review. J Eur Acad Dermatol Venereol 2007;21:17-24
144. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional risk factors. Arthritis Rheum 2001;44:2737-45
145. De Vera MA, Choi H, Abrahamowicz M, et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a populationbased study. Arthritis Care Res (Hoboken) 2012;64:809-16
146. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative out-comes in patients undergoing cardiac surgery: a metaanalysis of over 30,000 patients. Eur Heart J 2008;29:1548-59
147. Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22(5):939-46
148. Iannuzzi JC, Rickles AS, Kelly KN, et al. Perioperative pleiotropic statin effects in general surgery. Surgery 2014;155(3):398-407
149. Lindenauer PK, Pekow P, Wang K, et al. Lipid lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291(17):2092-9
150. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105(6):1260-72
151. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009;30(22):2769-812
152. Le Manach Y, Godet G, Coriat P, et al. The impact of post-operative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326-33
153. Kristensen SD, Knuuti J, Saraste A, et al. Authors/Task Force Members. 2014 ESC/EAS Guidelines on noncardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2014;35(35):2383-431
154. Degreef LE, Opdam FL, Teepe-Twiss IM, et al. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur J Intern Med 2010;21:293-6
155. Glueck CJ, Abuchaibe C, Wang P. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses 2011;77:658-61
156. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506
157. Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015; In press
158. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63(23):2541-8
159. Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3). ClinicalTrials.gov Identifier: NCT01984424
160. Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther 2015;20(2):157-68
161. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014;8(6):554-61
162. Guyton JR, Bays HE, Grundy SM, Jacobson TA; The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S72-81
163. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statinintolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33:1142-9
164. Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011;89:210-16
165. Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocrinol Metab 2013;17:977-82
166. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prevent Cardiol 2014;21(4):464-74
167. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87
168. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C
169. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4-15
170. Bays H, Cohen DE, Chalasani N, Harrison SA; The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S47-57
171. Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013;7(5):472-83
172. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008;337:a2286
173. Phillips PS, Haas RH, Bannykh S, et al. Statin-Associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
174. Abukres SH, Hoti K, Hughes JD. Patient attitudes towards a new role for pharmacists: continued dispensing. Patient Prefer Adherence 2014;8:1143-51
175. Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. CHEST J 2008;134(4):824-30
176. Vandiver W, Hunter ML. Statin adverse effects: Sorting out the evidence. Fam Pract 2013;62:730
177. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996;313(7058):649-51
178. Olson MB, Kelsey SF, Matthews KA, et al. Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. J Womens Health 2008;17(2):187-94
179. Kang J-H, Kao L-T, Lin H-C, et al. Statin use increases the risk of depressive disorder in stroke patients: A populationbased study. J Neurol Sci 2015;348(1-2):89-93
180. Amarenco P, Bogousslavsky J, Callahan A; Investigators SPbARiCL. High-dose atorvastatin after stroke or transient ischemic attack. J Vasc Surg 2006;44(6):1374
181. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004;97(4):229-35
182. Tuccori M, Lapi F, Testi A, et al. Statin-Associated psychiatric adverse events. Drug Saf 2008;31(12):1115-23
183. Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother 2001;35(10):1292
184. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. Bmj 2013;346:f2610
185. Segal AS. Alopecia associated with atorvastatin. Am J Med 2002;113(2):171
186. Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol 2006;47(1):57-9
187. Adcock B, Hornsby L, Jenkins K. Dermographism: an adverse effect of atorvastatin. J Am Board Fam Pract 2001;14(2):148-51
188. Anliker M, Wüthrich B. Chronic urticaria to atorvastatin. Allergy 2002;57(4):366
189. Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. JAMA 1998;279(20):1613-14
190. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993;186(4):248-52
191. Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 2013;131(11):1427-34
192. Fraunfelder F, Richards AB. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Ophthalmology 2008;115(12):2282-5
193. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43(4):589-99
194. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
195. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-Analysis of randomized trials. J Sex Med 2014;11(7):1626-35
196. De Graaf L, Brouwers A, Diemont W. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? Br J Clin Pharmacol 2004;58(3):326-8
197. Roberto G, Biagi C, Montanaro N, et al. Statin-Associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol 2012;68(6):1007-11
198. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and metaanalysis of randomized controlled trials. BMC Med 2013;11:57
199. Groneberg DA, Barkhuizen A, Jeha T. Simvastatin-induced thrombocytopenia. Am J Hematol 2001;67(4):277
200. McCarthy LJ, Porcu P, Fausel CA, et al. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998;352(9136):1284-5
201. McCarthy LJ, Dlott JS, Orazi A, et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004;8(2):80-6